News

Avammune Therapeutics raises $12 million to advance cancer therapies

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

1179 Discovery of a first-in-class ADAR1 p150 inhibitor targeting the Zα-domain with potent anti-tumor efficacy in syngeneic mouse models
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2025, 13 (Suppl 2) A1344; DOI:10.1136/jitc-2025-SITC2025.1179

624 AVA-NP-695 demonstrates strong anti-cancer activity in ICB-refractory & rare cancers
Borja Ruiz Fernandez de Cordoba, Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Alejandro Sweet-cordero, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2025, 13 (Suppl 2) A710; DOI:10.1136/jitc-2025-SITC2025.0624

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics